Actelion talking to Sanofi after J&J exit

By Oliver Hirt and Pamela Barbaglia ZURICH/LONDON (Reuters) - Switzerland's Actelion Ltd is in talks with French drugmaker Sanofi about a deal, sources said on Wednesday, after U.S. healthcare group Johnson & Johnson abandoned efforts to buy the company. Actelion's shares ended 9 percent lower on investor concern that J&J's exit underlined the challenges facing any bidder for Europe's biggest biotech group. One option under consideration is for Sanofi to give shareholders a so-called con